James Shin

is the low single digit headwind being realized? If so, is it somehow being blended where Humira is seeing outsized headwinds

Any color on the indication for the MARITIME trials that will start in the first half '25? And can you say anything on whether or not MARITIME will have head-to-head against incumbents

once Cristian settled to his seat, what sort of changes can we expect from the early-stage pipeline

is there an initial data point or policy decision that will inform next steps

does the data look consistent? Does it look competitive to PD one

What are BMY's expectations for the PANscore benefit? And then -- any color on how ADP 2 will be disclosed

could you just give us an update on Yeztugo's buy-and-bill and white bagging mix

there were some price benefits to Descovy. But is there any read-through or implications to LEN's launch

will 989's EHA update be mostly a check-the-box kind of update? Or will there be some new wrinkles to glean

can you say whether or not we should expect SVR, TSS and anemia burden, at least on the kinetics front to look similar to rux

Did these crossover patients experience rapid pain reduction from the week like, we saw in week twelve?

How will you disclose this data? Will we get a press release with high score top-line followed by full data at a

Is Lilly working with stakeholders on revisions to secure longer-term Medicare access?

can you share any similarities or differences you foresee with what you went through previously during the Part D senior savings model for insulins $35 co-pay rollout

does that suggest greater GTM pressure than what you would normally have with rebates? Does this make clinical profiles more relevant to form like positioning or access

is the mid to high single-digit price headwind still intact following the CVS formulary decision on Zepbound and also given the movement in FX?

can you go over how this titration schedule may impact the Phase II weight loss, A1c and safety results published in Lancet and New England Journal?

Can you help us distinguish MK-6837 from sac-TMT? And then just going back to the TL1A question

On Cadence's ACA presentation, can you help level state what we should and should not expect to learn

was Merck notified of Sino Biopharm's interest in LaNova? And does that have any bearing on Merck's commitment to 2010

is there a need for more or room for more US CapEx? And is it pending US tax reform

there is an upcoming February 2025 ACIP meeting, and the agenda suggests there's some follow-up on last October